About OneCell Diagnostics
OneCell Diagnostics is a company based in Cupertino (United States) founded in 2021 by Mohan Uttarwar and Aravindan Vasudevan. It operates as a B2B, and SaaS. OneCell Diagnostics has raised $16 million across 1 funding round from investors including Cedars Sinai, Tenacity Ventures and Celesta. The company has 33 employees as of March 31, 2023. OneCell Diagnostics offers products and services including OncoIndx, OncoDiscover, OncoMonitor, OncoRisk, and iCare. OneCell Diagnostics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.
- Headquarter Cupertino, United States
- Employees 33 as on 31 Mar, 2023
- Founders Mohan Uttarwar, Aravindan Vasudevan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Onecell Diagnostics India Private Limited
- Date of Incorporation 20 Dec, 2021
- Jurisdiction Pune, Maharashtra, India
-
Annual Revenue
$1.38 M (USD)624.26as on Mar 31, 2023
-
Net Profit
$5.36 K (USD)1.35as on Mar 31, 2023
-
EBITDA
$-1.19 M (USD)-50341.75as on Mar 31, 2023
-
Total Equity Funding
$16 M (USD)
in 1 rounds
-
Latest Funding Round
$16 M (USD), Series A
Nov 20, 2024
-
Investors
Cedars Sinai
& 4 more
-
Employee Count
33
as on Mar 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OneCell Diagnostics
OneCell Diagnostics offers a comprehensive portfolio of products and services, including OncoIndx, OncoDiscover, OncoMonitor, OncoRisk, and iCare. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Comprehensive genomic profiling for detecting cancer alterations and insights.
Detects circulating tumor cells to assess cancer metastasis risks.
Monitors cancer progression through blood-based disease tracking.
Evaluates hereditary cancer risks via gene panel analysis.
AI application for personalized cancer treatment and monitoring.
Tool for analyzing research data in oncology studies.
Unlock access to complete
Funding Insights of OneCell Diagnostics
OneCell Diagnostics has successfully raised a total of $16M through 1 strategic funding round. The most recent funding activity was a Series A round of $16 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $16.0M
-
First Round
First Round
(20 Nov 2024)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Series A - OneCell Diagnostics | Valuation | Celesta Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OneCell Diagnostics
OneCell Diagnostics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Cedars Sinai, Tenacity Ventures and Celesta. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Technology investment firm focusing on early-growth stages and software businesses in India.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OneCell Diagnostics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OneCell Diagnostics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Onecell Diagnostics Comparisons
Competitors of OneCell Diagnostics
OneCell Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Onecell Diagnostics
Frequently Asked Questions about OneCell Diagnostics
When was OneCell Diagnostics founded?
OneCell Diagnostics was founded in 2021 and raised its 1st funding round 3 years after it was founded.
Where is OneCell Diagnostics located?
OneCell Diagnostics is headquartered in Cupertino, United States. It is registered at Cupertino, California, United States.
Who is the current CEO of OneCell Diagnostics?
Mohan Uttarwar is the current CEO of OneCell Diagnostics. They have also founded this company.
Is OneCell Diagnostics a funded company?
OneCell Diagnostics is a funded company, having raised a total of $16M across 1 funding round to date. The company's 1st funding round was a Series A of $16M, raised on Nov 20, 2024.
How many employees does OneCell Diagnostics have?
As of Mar 31, 2023, the latest employee count at OneCell Diagnostics is 33.
What is the annual revenue of OneCell Diagnostics?
Annual revenue of OneCell Diagnostics is $1.38M as on Mar 31, 2023.
What does OneCell Diagnostics do?
OneCell Diagnostics focuses on precision oncology by developing advanced genomic and AI-based tests for cancer detection and management. They provide services like blood tests for circulating tumor cells and longitudinal monitoring tools. Operating from offices in the United States and India, they serve healthcare providers, patients, and researchers with data analytics platforms to improve treatment decisions and outcomes.
Who are the top competitors of OneCell Diagnostics?
OneCell Diagnostics's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
What products or services does OneCell Diagnostics offer?
OneCell Diagnostics offers OncoIndx, OncoDiscover, OncoMonitor, OncoRisk, and 2 more products and services.
Who are OneCell Diagnostics's investors?
OneCell Diagnostics has 5 investors. Key investors include Cedars Sinai, Tenacity Ventures, Celesta, Eragon, and Singularity Venture Partners.